Purchase of Rapid Syndromic Molecular Testing Reagents for Seattle VAMC
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
260-NETWORK CONTRACT OFFICE 20 (36C260)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36C26026Q0905
NAICS
325413 - In-Vitro Diagnostic Substance Manufacturing
Classification Code
6515
Additional Details
Documents2
The Department of Veterans Affairs, through its Network Contract Office 20 (36C260), has issued a Sources Sought notice for the procurement of rapid syndromic molecular testing reagents for the Seattle VA Medical Center, located in Seattle, Washington. This initiative is intended to support the medical center’s diagnostic capabilities by ensuring access to advanced, rapid molecular testing reagents, which are essential for timely and accurate syndromic diagnosis in clinical settings.
The scope of this procurement encompasses the supply of in-vitro diagnostic substances, specifically rapid syndromic molecular testing reagents. These reagents are critical for the medical center’s laboratory operations, enabling efficient detection and identification of various syndromes through molecular methods. The intended outcome is to enhance patient care by providing clinicians with reliable tools for rapid diagnosis, thereby facilitating prompt treatment decisions and improving overall healthcare delivery for veterans.
Key requirements for this opportunity include the provision of reagents that meet the standards of in-vitro diagnostic substance manufacturing, as classified under NAICS Code 325413. The Product Service Code associated with this procurement is 6515, which pertains to medical and surgical instruments, equipment, and supplies. Contractors are expected to supply reagents that are compatible with the medical center’s existing diagnostic platforms and adhere to all relevant regulatory and quality standards.
The notice does not specify any set-aside requirements, indicating that the procurement is open to all qualified vendors without restrictions related to small business status or other socioeconomic categories. Interested parties should review the attached documents for further details regarding technical specifications, quantities, and any additional requirements.
The contracting entity responsible for this acquisition is the 260-Network Contract Office 20, a federal office within the Department of Veterans Affairs. The primary point of contact for this notice is Hector D. Baltazar ([email protected]), with James Harris ([email protected]) listed as the secondary contact. The place of performance is Seattle, Washington, and all deliverables are expected to be provided to the Seattle VA Medical Center.
This notice is currently active, with a response deadline set for August 6, 2027. Contractors interested in this opportunity are encouraged to access the full notice and attachments via the SAM.gov portal (Opportunity ID: cd84c5c8e6ce48008adc1f8fddacb384) for comprehensive information and submission instructions.
Overall, this procurement represents a significant opportunity for suppliers of in-vitro diagnostic reagents to support the VA’s mission of delivering high-quality healthcare to veterans. Contractors should ensure their offerings align with the outlined requirements and be prepared to demonstrate their capability to meet the medical center’s needs throughout the contract lifecycle.